| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2718 |
| Trial ID | NCT04932863 |
| Disease | Neoplasm |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia |
| Recruitment status | Unknown |
| Title | A Prospective Observational Non Interventional Study of Reactogenicity and Safety of the BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment |
| Year | 2021 |
| Country | Italy |
| Company sponsor | Ente Ospedaliero Ospedali Galliera |
| Other ID(s) | 35UCS2021 |
| Vector information | |||
|
|||
| Cohort1: active surveillance | |||||||||||
|
|||||||||||
| Cohort2: chemotherapy | |||||||||||
|
|||||||||||
| Cohort3: hormone therapy | |||||||||||
|
|||||||||||
| Cohort4: targeted therapy | |||||||||||
|
|||||||||||
| Cohort5: ICI | |||||||||||
|
|||||||||||